These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 28054552)

  • 1. c-Src phosphorylation and activation of hexokinase promotes tumorigenesis and metastasis.
    Zhang J; Wang S; Jiang B; Huang L; Ji Z; Li X; Zhou H; Han A; Chen A; Wu Y; Ma H; Zhao W; Zhao Q; Xie C; Sun X; Zhou Y; Huang H; Suleman M; Lin F; Zhou L; Tian F; Jin M; Cai Y; Zhang N; Li Q
    Nat Commun; 2017 Jan; 8():13732. PubMed ID: 28054552
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AKT1 Promotes Tumorigenesis and Metastasis by Directly Phosphorylating Hexokinases.
    Yu Y; Wang S; Wang Y; Zhang Q; Zhao L; Wang Y; Wu J; Han L; Wang J; Guo J; Xue J; Dong F; Zhang JH; Zhang L; Liu Y; Shi G; Zhang X; Li Y; Li J
    J Cell Biochem; 2024 Aug; 125(8):e30613. PubMed ID: 38860522
    [TBL] [Abstract][Full Text] [Related]  

  • 3. AKT2 phosphorylation of hexokinase 2 at T473 promotes tumorigenesis and metastasis in colon cancer cells via NF-κB, HIF1α, MMP2, and MMP9 upregulation.
    Li H; Lu S; Chen Y; Zheng L; Chen L; Ding H; Ding J; Lou D; Liu F; Zheng B
    Cell Signal; 2019 Jun; 58():99-110. PubMed ID: 30877036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. c-Src Promotes Tumorigenesis and Tumor Progression by Activating PFKFB3.
    Ma H; Zhang J; Zhou L; Wen S; Tang HY; Jiang B; Zhang F; Suleman M; Sun D; Chen A; Zhao W; Lin F; Tsau MT; Shih LM; Xie C; Li X; Lin D; Hung LM; Cheng ML; Li Q
    Cell Rep; 2020 Mar; 30(12):4235-4249.e6. PubMed ID: 32209481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of lentivirus-mediated shRNA inactivation of HK1, HK2, and HK3 genes in colorectal cancer and melanoma cells.
    Kudryavtseva AV; Fedorova MS; Zhavoronkov A; Moskalev AA; Zasedatelev AS; Dmitriev AA; Sadritdinova AF; Karpova IY; Nyushko KM; Kalinin DV; Volchenko NN; Melnikova NV; Klimina KM; Sidorov DV; Popov AY; Nasedkina TV; Kaprin AD; Alekseev BY; Krasnov GS; Snezhkina AV
    BMC Genet; 2016 Dec; 17(Suppl 3):156. PubMed ID: 28105937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Tumor Agnostic Therapeutic Strategy for Hexokinase 1-Null/Hexokinase 2-Positive Cancers.
    Xu S; Herschman HR
    Cancer Res; 2019 Dec; 79(23):5907-5914. PubMed ID: 31434645
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fubp1 supports the lactate-Akt-mTOR axis through the upregulation of Hk1 and Hk2.
    Kang M; Lee SM; Kim W; Lee KH; Kim DY
    Biochem Biophys Res Commun; 2019 Apr; 512(1):93-99. PubMed ID: 30871777
    [TBL] [Abstract][Full Text] [Related]  

  • 8. FOXM1 promotes reprogramming of glucose metabolism in epithelial ovarian cancer cells via activation of GLUT1 and HK2 transcription.
    Wang Y; Yun Y; Wu B; Wen L; Wen M; Yang H; Zhao L; Liu W; Huang S; Wen N; Li Y
    Oncotarget; 2016 Jul; 7(30):47985-47997. PubMed ID: 27351131
    [TBL] [Abstract][Full Text] [Related]  

  • 9. ErbB2-upregulated HK1 and HK2 promote breast cancer cell proliferation, migration and invasion.
    Ma X; Chen J; Huang B; Fu S; Qu S; Yu R; Zhao Y
    Med Oncol; 2023 Apr; 40(5):154. PubMed ID: 37079118
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A non-catalytic scaffolding activity of hexokinase 2 contributes to EMT and metastasis.
    Blaha CS; Ramakrishnan G; Jeon SM; Nogueira V; Rho H; Kang S; Bhaskar P; Terry AR; Aissa AF; Frolov MV; Patra KC; Brooks Robey R; Hay N
    Nat Commun; 2022 Feb; 13(1):899. PubMed ID: 35173161
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dual-faced SH3BGRL: oncogenic in mice, tumor suppressive in humans.
    Wang H; Liu B; Al-Aidaroos AQ; Shi H; Li L; Guo K; Li J; Tan BC; Loo JM; Tang JP; Thura M; Zeng Q
    Oncogene; 2016 Jun; 35(25):3303-13. PubMed ID: 26455318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A causal link from ALK to hexokinase II overexpression and hyperactive glycolysis in EML4-ALK-positive lung cancer.
    Ma Y; Yu C; Mohamed EM; Shao H; Wang L; Sundaresan G; Zweit J; Idowu M; Fang X
    Oncogene; 2016 Nov; 35(47):6132-6142. PubMed ID: 27132509
    [TBL] [Abstract][Full Text] [Related]  

  • 13. SILAC Quantitative Proteomics and Biochemical Analyses Reveal a Novel Molecular Mechanism by Which ADAM12S Promotes the Proliferation, Migration, and Invasion of Small Cell Lung Cancer Cells through Upregulating Hexokinase 1.
    Duan Q; Li D; Xiong L; Chang Z; Xu G
    J Proteome Res; 2019 Jul; 18(7):2903-2914. PubMed ID: 31117637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The transmembrane adaptor Cbp/PAG1 controls the malignant potential of human non-small cell lung cancers that have c-src upregulation.
    Kanou T; Oneyama C; Kawahara K; Okimura A; Ohta M; Ikeda N; Shintani Y; Okumura M; Okada M
    Mol Cancer Res; 2011 Jan; 9(1):103-14. PubMed ID: 21156787
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hexokinase 2 confers resistance to cisplatin in ovarian cancer cells by enhancing cisplatin-induced autophagy.
    Zhang XY; Zhang M; Cong Q; Zhang MX; Zhang MY; Lu YY; Xu CJ
    Int J Biochem Cell Biol; 2018 Feb; 95():9-16. PubMed ID: 29247711
    [TBL] [Abstract][Full Text] [Related]  

  • 16. c-Src facilitates tumorigenesis by phosphorylating and activating G6PD.
    Ma H; Zhang F; Zhou L; Cao T; Sun D; Wen S; Zhu J; Xiong Z; Tsau MT; Cheng ML; Hung LM; Zhou Y; Li Q
    Oncogene; 2021 Apr; 40(14):2567-2580. PubMed ID: 33686238
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The decrease of glycolytic enzyme hexokinase 1 accelerates tumor malignancy via deregulating energy metabolism but sensitizes cancer cells to 2-deoxyglucose inhibition.
    Tseng PL; Chen CW; Hu KH; Cheng HC; Lin YH; Tsai WH; Cheng TJ; Wu WH; Yeh CW; Lin CC; Tsai HJ; Chang HC; Chuang JH; Shan YS; Chang WT
    Oncotarget; 2018 Apr; 9(27):18949-18969. PubMed ID: 29721175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Proline-rich tyrosine kinase 2 (Pyk2) promotes proliferation and invasiveness of hepatocellular carcinoma cells through c-Src/ERK activation.
    Sun CK; Man K; Ng KT; Ho JW; Lim ZX; Cheng Q; Lo CM; Poon RT; Fan ST
    Carcinogenesis; 2008 Nov; 29(11):2096-105. PubMed ID: 18765415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metabolic phenotype of bladder cancer.
    Massari F; Ciccarese C; Santoni M; Iacovelli R; Mazzucchelli R; Piva F; Scarpelli M; Berardi R; Tortora G; Lopez-Beltran A; Cheng L; Montironi R
    Cancer Treat Rev; 2016 Apr; 45():46-57. PubMed ID: 26975021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The proto-oncogene c-Src and its downstream signaling pathways are inhibited by the metastasis suppressor, NDRG1.
    Liu W; Yue F; Zheng M; Merlot A; Bae DH; Huang M; Lane D; Jansson P; Lui GY; Richardson V; Sahni S; Kalinowski D; Kovacevic Z; Richardson DR
    Oncotarget; 2015 Apr; 6(11):8851-74. PubMed ID: 25860930
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.